Hypervascular Tumors clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 22 years and up
To determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non-inferior to) standard of care (SOC) transarterial embolization/conventional transarterial chemoembolization, while resulting in an acceptable risk of device and procedure-related serious adverse events.
at UC Irvine UCLA